Neurochemical predictors of response to pharmacologic treatments for bipolar disorder

被引：16

作者：

DelBello M.P. ^{[1
]}

Strakowski S.M. ^{[1
]}

机构：

[1] Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267

来源：

Current Psychiatry Reports | 2004年 / 6卷 / 6期

关键词：

Lithium; Bipolar Disorder; Magnetic Resonance Spectroscopy; Biol Psychiatry; Bipolar Patient;

D O I：

10.1007/s11920-004-0012-1

中图分类号：

学科分类号：

摘要：

Bipolar disorder is a common psychiatric disorder that is characterized by recurrent episodes of mania and often depression. Mood stabilizers and antipsychotics are first-line pharmacologic options for patients with bipolar disorder. However, the exact mechanisms by which these medications exert the mood stabilizing effects are unknown. Additionally, individuals with bipolar disorder often try several medications unsuccessfully before achieving mood stabilization. Magnetic resonance spectroscopy (MRS) is a noninvasive neuroimaging technique that can be used to identify the neurochemical effects and predictors of response to medications commonly used to treat bipolar disorder. MRS may facilitate targeted treatment interventions and decrease the morbidity and mortality associated with this illness. Examining the mechanisms of action of pharmacologic agents used to treat bipolar disorder may clarify the neurophysiologic basis of bipolar disorder. We will review recent MRS investigations that have evaluated the neurochemical effects of pharmacologic treatments and predictors of treatment response in patients with bipolar disorder. Copyright © 2004 by Current Science Inc.

引用

页码：466 / 472

页数：6

共 58 条

[1]

Lish J.D., Dime-Meenan S., Whybrow P.C., Et al., The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members, J. Affect. Disord., 31, pp. 281-294, (1994)

[2]

Kessler R.C., McGonagle K.A., Zhao S., Et al., Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey, Arch. Gen. Psychiatry, 51, pp. 8-19, (1994)

[3]

Lewinsohn P.M., Klein D.N., Seeley J.R., Bipolar disorder during adolescence and young adulthood in a community sample, Bipolar Disord., 2, pp. 281-293, (2000)

[4]

Frye M.A., Ketter T.A., Leverich G.S., Et al., The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study, J. Clin. Psychiatry, 61, pp. 9-15, (2000)

[5]

Bhangoo R.K., Lowe C.H., Myers F.S., Et al., Medication use in children and adolescents treated in the community for bipolar disorder, J. Child Adolesc. Psychopharmacol., 13, pp. 515-522, (2003)

[6]

Gelenberg A.J., Pies R., Matching the bipolar patient and the mood stabilizer, Ann. Clin. Psychiatry, 15, pp. 203-216, (2003)

[7]

Bowden C.L., Predictors of response to divalproex and lithium, J. Clin. Psychiatry, 56, pp. 25-30, (1995)

[8]

Soares J.C., Krishnan K.R., Keshavan M.S., Nuclear magnetic resonance spectroscopy: New insights into the pathophysiology of mood disorders, Depression, 4, pp. 14-30, (1996)

[9]

Kato T., Inubushi T., Kato N., Magnetic resonance spectroscopy in affective disorders, J. Neuropsychiatry Clin. Neurosci., 10, pp. 133-147, (1998)

[10]

Post R.M., Speer A.M., Hough C.J., Et al., Neurobiology of bipolar illness: Implications for future study and therapeutics, Ann. Clin. Psychiatry, 15, pp. 85-94, (2003)

← 1 2 3 4 5 6 →